drugset / Trial / NCT05077930
Convalescent Plasma Therapy for Hospitalized Patients With COVID-19
Phase 2
Completed
38 enrolled
Tânia Portella Costa
Centro de Hematologia e Hemoterapia do Paraná - Hemepar · collabFundação Oswaldo Cruz, Instituto Carlos Chagas, ICC Paraná · collabScience Valley Research Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Plasma from donors who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies to SARS-CoV-2 and may be a potential therapy for hospitalized patients with COVID-19. The efficacy of high-titer convalescent plasma for COVID-19, however, still unclear. The present study aims to evaluate the efficacy and safety of using convalescent plasma for treating hospitalized patients with COVID-19.
Timeline
- Start
- 2022-01-06
- Primary completion
- 2022-04-04
- Completion
- 2022-04-07
Publications
- Background Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020 Jul 10;7(7):CD013600. doi: 10.1002/14651858.CD013600.pub2.
- Costa TP, Aoki M, Ribeiro CM, Socca E, Itinose L, Basso R, Blanes L. Efficacy of convalescent plasma in hospitalized COVID-19 patients: findings from a controlled trial. Braz J Med Biol Res. 2024 Oct 7;57:e13627. doi: 10.1590/1414-431X2024e13627. eCollection 2024.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Convalescent Plasma | Protein / enzyme biologic | 200 ml | Other |
| Subject | Convalescent Plasma | Protein / enzyme biologic | 400 ml | Other |